Stockwatch: Those That Cannot Be Successful Raise Money
It struck me last week that that the quote attributed to George Bernard Shaw – "He who can, does. He who cannot, teaches." – can be modified to apply to an increasing cadre of small- and mid-capitalization life science companies. Success for these companies that resonates with investors is either to be acquired or to reach a valuation that is too big to be acquired. The opposite of success is not so easy to define since clinical, regulatory or commercial failure usually means coming back to investors for a bail out.
You may also be interested in...
Amarin's stock price fell 18.4% to $9.75 per share in after-hours trading on 6 December after the company announced that it raised $100 million in non-equity financing from an investment fund managed by Pharmakon Advisors to support commercialization of its prescription fish oil pill Vascepa (icosapent ethyl) without a partner.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.